These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2448889)

  • 21. A simplified assay method for platelet factor 4 in plasma and in platelets with a chromogenic substrate.
    Vinazzer H
    Haemostasis; 1978; 7(6):352-8. PubMed ID: 720957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The interaction of platelet factor four and glycosaminoglycans.
    Loscalzo J; Melnick B; Handin RI
    Arch Biochem Biophys; 1985 Jul; 240(1):446-55. PubMed ID: 2409923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of thrombin by antithrombin III and heparin cofactor II in vivo.
    Liu L; Dewar L; Song Y; Kulczycky M; Blajchman MA; Fenton JW; Andrew M; Delorme M; Ginsberg J; Preissner KT
    Thromb Haemost; 1995 Mar; 73(3):405-12. PubMed ID: 7545318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of continuous low-dose intravenous heparin administered during operation on postoperative measurements of antithrombin III and antifactor Xa.
    Jennings SA; Heather BP; Greenhalgh RM
    Surgery; 1984 Sep; 96(3):550-5. PubMed ID: 6474360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Significance of the amidolytic method in the typing of congenital antithrombin III deficiency].
    Losonczy H; Nagy I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):184-8. PubMed ID: 6177603
    [No Abstract]   [Full Text] [Related]  

  • 29. Automated determination of heparin with chromogenic substrates.
    van Putten J; van de Ruit M; Beunis M; Hemker HC
    Haemostasis; 1984; 14(2):184-94. PubMed ID: 6735276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Control of the therapeutic heparin dosage in platelet rich citrate plasma after protamine neutralization].
    Görss EW; Maercker W
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(6):815-22. PubMed ID: 2436996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombin-III and platelets in haemodialysis patients.
    Brandt P; Jespersen J; Sørensen LH
    Nephron; 1981; 28(1):1-3. PubMed ID: 7266723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Assay of plasma heparin and heparin-antithrombin III complex--studies in normal volunteers and thromboembolic patients].
    Oguma Y; Hasegawa H; Nagata H; Kawakami Y
    Rinsho Ketsueki; 1986 May; 27(5):723-9. PubMed ID: 3747167
    [No Abstract]   [Full Text] [Related]  

  • 34. The consumption of antithrombin III during coagulation, its consequences for the calculation of prothrombinase activity and the standardisation of heparin activity.
    Béguin S; Kessels H; Dol F; Hemker HC
    Thromb Haemost; 1992 Aug; 68(2):136-42. PubMed ID: 1412157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dextran sulphate inhibits phospholipid and sulphatide mediated autoactivation of factor XII.
    Schousboe I; Rasmussen MS; Lintner R
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):503-9. PubMed ID: 7841305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The inhibition of the anticoagulant activity of heparin by platelets, brain phospholipids, and tissue factor.
    Ofosu FA; Cerskus AL; Hirsh J; Smith LM; Modi GJ; Blajchman MA
    Br J Haematol; 1984 Jun; 57(2):229-38. PubMed ID: 6733045
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High molecular weight forms of antithrombin III complexes in blood.
    Marciniak E; Gora-Maslak G
    Thromb Haemost; 1983 Feb; 49(1):32-6. PubMed ID: 6845270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive chromogenic anti-factor Xa assay and its use in the classification of antithrombin deficiencies.
    Kovács B; Bereczky Z; Selmeczi A; Gindele R; Oláh Z; Kerényi A; Boda Z; Muszbek L
    Clin Chem Lab Med; 2014 Dec; 52(12):1797-806. PubMed ID: 24968404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
    Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
    Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The changes and relation among platelet function, plasma heparin and anti-coagulation-III: activity in patients with hemorrhagic fever with renal syndrome].
    Wei L; Pan X; Yu Y; Lu Q
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Jun; 11(2):163-5. PubMed ID: 15619827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.